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The renin-angiotensin-system (RAS) constitutes an important hormonal system in the phys-
iological regulation of blood pressure. Indeed, dysregulation of the RAS may lead to the
development of cardiovascular pathologies including kidney injury. Moreover, the blockade
of this system by the inhibition of angiotensin converting enzyme (ACE) or antagonism of
the angiotensin type 1 receptor (AT1R) constitutes an effective therapeutic regimen. It is
now apparent with the identification of multiple components of the RAS that the system
is comprised of different angiotensin peptides with diverse biological actions mediated
by distinct receptor subtypes. The classic RAS can be defined as the ACE-Ang II-AT1R
axis that promotes vasoconstriction, sodium retention, and other mechanisms to main-
tain blood pressure, as well as increased oxidative stress, fibrosis, cellular growth, and
inflammation in pathological conditions. In contrast, the non-classical RAS composed of
the ACE2-Ang-(1–7)-Mas receptor axis generally opposes the actions of a stimulated Ang II-
AT1R axis through an increase in nitric oxide and prostaglandins and mediates vasodilation,
natriuresis, diuresis, and oxidative stress. Thus, a reduced tone of the Ang-(1–7) system
may contribute to these pathologies as well. Moreover, the non-classical RAS components
may contribute to the effects of therapeutic blockade of the classical system to reduce
blood pressure and attenuate various indices of renal injury. The review considers recent
studies on the ACE2-Ang-(1–7)-Mas receptor axis regarding the precursor for Ang-(1–7), the
intracellular expression and sex differences of this system, as well as an emerging role of
the Ang1-(1–7) pathway in fetal programing events and cardiovascular dysfunction.
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INTRODUCTION
Over the past 20 years the concept of the renin-angiotensin-system
(RAS) as a monolithic endocrine system reflected primarily by the
interaction of the peptide Angiotensin II (Ang II) with the AT1-
receptor subtype has undergone extensive revision. The emerging
view of alternative pathways within the RAS that may function-
ally antagonize the Ang II-AT1-receptor axis may be traced back
to both the characterization of the AT2 receptor subtype and the
identification of the heptapeptide des-[Phe8]-Angiotensin II or
Angiotensin-(1–7) [Ang-(1–7)] in the circulation and various tis-
sues (1–4). Since that time, the elaboration of distinct biochemical
components that comprise the “Ang-(1–7) axis” is now firmly
established with the identification of a unique receptor for Ang-
(1–7) – the G-protein coupled Mas receptor, selective antagonists
and agonists for the receptor, and an angiotensin II converting
enzyme (ACE2) that catalyzes the processing of Ang II to Ang-(1–
7) (5–9). In addition to the identification of the components of
the Ang-(1–7) system, there is the recognition of various signaling
pathways including nitric oxide (NO), prostaglandins, and cellular
phosphatases that are stimulated by the peptide (10, 11). Although
the early studies of Ang-(1–7) primarily sought to establish a role
for Ang-(1–7) in the regulation of blood pressure, particularly
as endogenous levels of the peptide increase markedly following
angiotensin converting enzyme (ACE) or AT1-receptor blockade;
the pressure-independent actions of the Ang-(1–7) axis should be
considered with perhaps equal importance (6, 12, 13). Indeed,
the beneficial actions of Ang-(1–7) system encompass various
pathologies from cancer and the anti-proliferative actions of the
peptide to diabetes and the cellular effects on stem cells (8, 9, 14). In
turn, deficiencies in Ang-(1–7) that contribute to autonomic dys-
function were apparent in hypertension (15) and aging (16); Ang-
(1–7) deficiency in hypertension was restored by ACE inhibitor
treatment (17) or chronic Ang-(1–7) replacement (18). The
breadth of these effects is not surprising as the RAS is a tissue sys-
tem whose protein and peptide components are expressed in essen-
tially every organ and whose actions are implicated in numerous
physiological events that influence renal, neuronal, cardiac, pan-
creatic, vascular, adrenal, pituitary, cognitive, aging, inflammatory,
and reproductive functions (19). As the Ang II-AT1-receptor axis
of the RAS is increasingly recognized as a key regulatory pathway
in various tissues and cells, the counter-balancing Ang-(1–7) axis
should be evident as well. In this review, we consider the current
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literature on the ACE2-Ang-(1–7)-Mas receptor axis regarding the
sources for Ang-(1–7), the intracellular expression of this system,
the emerging role of Ang1-(1–7) pathway in fetal programing
events and cardiovascular dysfunction, and finally, the evidence
for sex-dependent regulation and function of the Ang-(1–7) axis.
SOURCES OF ANGIOTENSIN-(1–7)
ENDOPEPTIDASES
Angiotensinogen, a glycosylated protein that is primarily synthe-
sized and secreted by the liver as well as other tissues is the sole
precursor for angiotensin peptides (20). The only known substrate
for the aspartyl protease renin is angiotensinogen which releases
the decapeptide Ang I from the amino-terminal portion of the
protein (Figure 1). Ang I is then cleaved by ACE to form the bioac-
tive peptide Ang II. Early studies revealed that endogenous levels
of both Ang I and Ang-(1–7) were markedly increased following
the administration of ACE inhibitors (21, 22). The augmented
response in Ang-(1–7) suggested that the circulating peptide may
contribute to the beneficial actions of the inhibition of ACE path-
way in addition to that of reducing endogenous levels of Ang II.
The increase in Ang-(1–7) in the presence of ACE blockade neces-
sitates a processing pathway independent of the formation of Ang
II. Several studies subsequently showed that the endopeptidase
3.4.24.11 (neprilysin) contributed to the circulating levels of Ang-
(1–7) in animals chronically treated with various ACE inhibitors
(23–26). Ang I infusion in normotensive WKY and hyperten-
sive spontaneously hypertensive rat (SHR) treated with the ACE
inhibitor lisinopril resulted in higher plasma levels of Ang-(1–7)
and co-administration of the neprilysin inhibitor SCH39370 but
not the prolyl oligopeptidase (POP) inhibitor z-prolyl prolinal
abolished the circulating levels of the peptide (27). Moreover, acute
infusion of a similar dose of Ang II did not increase circulating
Ang-(1–7) in either control or lisinopril-treated WKY and SHR.
The increase in Ang-(1–7) following ACE blockade reflects both
a reduction in Ang-(1–7) metabolism and alternative process-
ing of Ang I through tissue-specific endopeptidases (23). In this
regard, Pereira et al. recently demonstrated that the endopeptidase
EC3.4.24.15 (thimet oligopeptidase) may contribute to formation
of Ang-(1–7) in the rat hippocampus (28). Interestingly, these
investigators reported higher expression of this peptidase and the
Mas receptor in a rat model of temporal lobe epilepsy suggesting
a possible role of the Ang-(1–7)-Mas axis in this central pathology
(28). Indeed, the study supports earlier reports of the direct pro-
cessing of Ang I to Ang-(1–7) by thimet oligopeptidase in vascular
smooth muscle cells and a rat hindlimb perfusion system (29, 30).
ACE2
Apart from endopeptidases that process Ang I or Ang-(1–12) to
Ang-(1–7), various mono-carboxypeptidases including prolyl car-
boxypeptidase (PCP), POP, and the ACE homolog ACE2 generate
Ang-(1–7) directly from Ang II. It should be emphasized that PCP
requires an acidic pH optimum for activity, but may contribute
to lysosomal pathways for metabolism of internalized Ang II or
to the processing of Ang II to Ang-(1–7) in urine (31). ACE2
continues to be of primary focus given its ability to effectively
metabolize Ang II and generate Ang-(1–7) (32, 33). ACE2 exhibits
an efficiency constant (Vmax/kM or kcat) for Ang II that is 10- to
FIGURE 1 | Enzymatic cascade of angiotensin peptide formation and
metabolism. Renin cleaves the precursor protein angiotensinogen to
angiotensin-(1–10) (Ang I) which is further processed to the biologically
active peptides Ang-(1–8) (Ang II) by angiotensin converting enzyme (ACE)
and Ang-(1–7) by endopeptidases such as neprilysin (NEP). Ang II undergoes
further processing at the carboxyl terminus by the carboxypeptidase ACE2
to yield Ang-(1–7) (Ang 7). Ang-(1–7) undergoes decarboxylation (DC) of the
aspartic acid residue to form Ala1-Ang-(1–7) (Ala1-Ang 7). The dodecapeptide
Ang-(1–12) is derived from the hydrolysis of the Tyr12-Tyr13 bond of rat
angiotensinogen by an unknown enzymatic pathway. Ang II recognizes both
AT1 and AT2 receptors. Ang-(1–7) activates the Mas receptor and
Ala1-Ang-(1–7) recognizes the Mas-D related receptor (Mrg).
100-fold higher than that of PC or POP. In this regard, the soluble
form of ACE2 has been utilized as a therapeutic agent to reduce
blood pressure and attenuate target organ damage in hypertensive
and diabetic animal models (34–37). ACE2 mRNA expression was
increased in the brain medulla following long-term AT1-receptor
blockade (38). It is unclear whether the beneficial effects of ACE2
administration reflect the reduction in Ang II, the enhanced for-
mation of Ang-(1–7) or the increased ratio of Ang-(1–7) to Ang II.
Moreover, Turner and colleagues report that soluble ACE2 attenu-
ated the integrin-dependent stimulation of focal adhesion kinase
(FAK) and increased the expression of the Akt kinase suggest-
ing the peptidase may have direct cellular effects apart from its
peptidase activity (39).
In addition to the functional role of ACE2 that catalyzes the
conversion of Ang II to Ang-(1–7), the peptidase may serve as
a biomarker of renal and cardiac pathologies. Two studies in
type I (streptozotocin-induced) and type II (db/db mice) dia-
betic models reported an early increase in the urinary excretion
of ACE2 (40, 41). The enhanced excretion of ACE2 in db/db mice
closely correlated to the increase in albuminuria or proteinuria.
Moreover, chronic treatment with insulin-sensitizing agent rosigli-
tazone improved the metabolic balance in the db/db mice and
reduced the excretion of both ACE2 and albumin (40). In con-
trast to the reduction in urinary levels of ACE2, the increased
renal expression of ACE2 in the db/db mouse was not altered by
rosiglitazone which may reflect an added therapeutic benefit to
maintain the peptidase in the diabetic kidney (40). An important
aspect of the two latter studies suggests that in the diabetic kid-
ney, the development of tissue injury should not necessarily be
interpreted as arising from a deficit in ACE2 expression. Indeed,
the increase in tissue and urinary levels of ACE2 in pathologi-
cal conditions may reflect a compensatory response to alter the
balance of Ang II and Ang-(1–7) pathways within a particular
tissue or cell type (7). In this regard, the deleterious effects of an
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ACE2 inhibitor or knockdown of the enzyme may be particularly
evident under conditions of enhanced ACE2 expression. The cir-
culating levels of ACE2, which are typically low to not detectable,
are also increased in experimental conditions of diabetes. We show
in a model of diabetic hypertension that circulating ACE2 activity
increased over fivefold in female mRen2.Lewis rats (42). However,
serum ACE activity also increased suggesting that the potential
beneficial effects of higher ACE2 may be offset by ACE acting to
increase Ang II and metabolize Ang-(1–7). Indeed, plasma lev-
els of Ang-(1–7) were not changed in the diabetic mRen2.Lewis
despite the marked increase in ACE2 activity. Moreover, circulat-
ing ACE activity was substantially higher than that of ACE2 when
assessed under similar incubation and substrate conditions for
each enzyme (42).
In the db/db mice, infusion of exogenous ACE2 that markedly
increased serum levels of the enzyme did not alter urinary ACE2
suggesting that the enzyme is not readily filtered by the glomerulus
(41). One mechanism for the increase in urinary excretion of ACE2
is the regulated shedding of the enzyme from the apical face of the
proximal tubules (Figure 2). Studies by Lambert and colleagues
originally reported that the disintegrin and metalloproteinase
(ADAM17) secretase was responsible for the release of ACE2 (43).
A subsequent report identified a specific sequence of the jux-
tamembrane stalk of ACE2 hydrolyzed that was by ADAM17 to
release the peptidase from human pulmonary epithelial cells (44).
In proximal epithelial cells of the db/db mouse kidney, there was
extensive overlap of ACE2 and ADAM17 immunostaining (40).
Moreover, rosiglitazone treatment attenuated ADAM17 expres-
sion which may contribute to the reduced shedding of ACE2 into
the tubular fluid and subsequent excretion in the urine. In addition
to the shedding of ACE2, ADAM17 may influence tissue damage
by the release of the tethered inflammatory factors TNFα, EGF,
and TGFα that subsequently activate their respective receptors in
an autocrine or paracrine manner (45). If expression of ACE2 on
the apical membrane of the tubules contributes to the regulation
of the local concentrations of Ang II, an increase in ADAM17
may lead to inflammatory and fibrotic events through enhanced
Ang II-AT1-receptor signaling, as well as increased cytokine and
growth factor activation (Figure 2). Lazartigues and colleagues
report that knockdown of ADAM17 in the brain of DOCA-salt
mice reduced blood pressure, and increased the tissue expression
of ACE2 (46). In this model of neurogenic hypertension, the ben-
efit of ADAM17 knockdown may reflect a reduction of Ang II
in brain; however, the direct effects on the release of EGF and
other cytokines cannot be discounted. Indeed, the transactivation
of the EGF receptor (EGFR) and signaling pathways is a key signal-
ing event of the Ang II-AT1-receptor pathway (47). The increased
shedding of ACE2 may also reduce levels of Ang-(1–7) and atten-
uate the inhibitory actions on the Ang II-AT1-receptor axis and
other pro-inflammatory and pro-fibrotic pathways. Akhtar et al.
recently reported that Ang-(1–7) attenuated EGFR activation in
response to Ang II, as well as reduced the extent of renal injury in
the diabetic SHR (48). Moreover, increasing evidence suggests that
one of the primary pathways activated by Ang-(1–7) is the stimu-
lation of various cellular phosphatases (PTP) including SHP-1 and
DUSP-1 that may attenuate activated kinase-dependent pathways
(49–53) (Figure 2).
FIGURE 2 | Scheme for the interaction of ACE2 andADAMs on the
apical surface of the proximal tubules in the diabetic kidney. Ang II
binds to the AT1 receptor (AT1R) and stimulates MAP kinase (MAPK)
pathways and production of reactive oxygen species (ROS). The Ang
II-AT1-receptor axis may attenuate ACE2 expression but increase ADAM
levels. ACE2 is anchored to the apical membrane and directly converts Ang
II to Ang-(1–7) (Ang 7); ACE also anchored to the membrane metabolizes
Ang-(1–7) to Ang-(1–5) (Ang 5). Ang-(1–7) recognizes the AT7/Mas receptor
(AT7R) to antagonize the actions of the Ang II-AT1R by stimulation of protein
phosphatases (PTP) and nitric oxide synthase (NOS) to form nitric oxide
(NO) and cGMP. In pathological conditions, increased expression of ADAMs
may hydrolyze ACE2 away from the apical surface to increase local
concentrations of Ang II and reduce the levels of Ang-(1–7).
ANGIOTENSIN-(1–12)
Nagata and colleagues identified a novel endogenous angiotensin
peptide termed Ang-(1–12) that contains the first 12 amino acids
of the N-terminal sequence of rat angiotensinogen (Asp1-Arg2-
Val3-Tyr4-Ile5-His6-Pro7-Phe8-His9-Leu10-Leu11-Tyr12) (54)
(Figure 1). These investigators developed antibodies directed to
the amino- and carboxyl-terminal sequences of Ang-(1–12) and
demonstrated expression of Ang-(1–12) in essentially all tissues
that contain Ang II with the highest levels in the intestine, brain,
heart, plasma, and kidney of rat. Differential expression of Ang-
(1–12) was evident in the heart and kidney of the SHR and the
normotensive control Wistar Kyoto strain (WKY) (55). An anti-
body specific to the C-terminal sequence of rat Ang-(1–12) includ-
ing Leu11-Tyr12 revealed selective staining in cardiac myocytes
and proximal tubule cells of the kidney. The site of hydrolysis
for formation of Ang-(1–12) from rat angiotensinogen occurs
at residues Tyr12-Tyr13 which is distinct from the Leu10-Leu11
sequence cleaved by renin to form Ang I. Thus, the generation of
Ang-(1–12) is likely through a non-renin dependent pathway and
may be apparent in conditions of low or suppressed renin activ-
ity, particularly with the use of selective renin inhibitors. Similar
to Ang I, Ang-(1–12) can be hydrolyzed at the Phe8-His9 bond
by ACE or chymase to form Ang II (54, 56, 57). The conversion
of Ang-(1–12) to Ang II by ACE in the circulation is consistent
with the acute increase in blood pressure following an infusion
of Ang-(1–12) in normotensive rats, as well as the blockade of
the pressor response by either an ACE inhibitor or AT1-receptor
antagonist. Arnold et al. also find that central Ang-(1–12) admin-
istration attenuated baroreflex sensitivity and the response was
blocked by either an ACE inhibitor or AT1-receptor antagonist
(57). Moreover, neutralization of Ang-(1–12) by intracerebroven-
tricular (ICV) infusion of an affinity-purified antibody reduced
blood pressure in the (mRen27)2 hypertensive rats consistent with
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the biochemical and immunocytochemical evidence for Ang-(1–
12) in the rat brain (58). To our knowledge, the latter study by
Isa and colleagues is the only report to date that demonstrates an
endogenous role for Ang-(1–12).
As to the Ang-(1–7) axis, we recently demonstrated that Ang-
(1–12) may be an alternative substrate for the generation Ang-
(1–7) in the kidney (59). Isolated cortical membranes from the
kidney of the hypertensive mRen2.Lewis rat processed Ang-(1–
12) to Ang-(1–7) and Ang-(1–4). We observed a similar pattern of
metabolism using the recombinant forms of mouse and human
neprilysin. The selective neprilysin inhibitor SCH39370 abolished
the formation of Ang-(1–7). We noted a peak corresponding to
Ang I in the processing of Ang-(1–12) by the cortical membranes
that was also abolished by the neprilysin inhibitor suggesting the
peptide may be an intermediate in the processing of Ang-(1–12)
to Ang-(1–7) (59). In these studies, we also show that circulat-
ing or renal renin did not metabolize Ang-(1–12) particularly in
the presence of the ACE inhibitor lisinopril which implies that
the peptide lacks the minimal sequence for recognition by renin
(59). Bujak-Gizycka and colleagues demonstrated the generation
of Ang-(1–12) in rat aorta homogenates by a serine peptidase
using Ang-(1–14) as the substrate; however, the extent that this
activity will process the angiotensinogen protein to Ang-(1–12)
is not currently known (60). We did not detect the conversion
of Ang-(1–12) to Ang-(1–7) in serum which would be consistent
with the lack of soluble forms of neprilysin in the circulation, nor
were there significant levels of Ang-(1–11) suggesting the absence
of processing by ACE2 or other carboxypeptidases (59). It is fea-
sible that Ang-(1–12) may be a potential substrate for Ang-(1–7)
through the initial conversion to Ang-(1–11) by ACE2 and subse-
quent processing to Ang-(1–9) and Ang-(1–7) by ACE. However,
ACE activity is far higher in the circulation than ACE2 and Ang-
(1–7) formation from Ang-(1–12) or Ang I more likely reflects
endopeptidase activity. Although further studies are required to
discern the endogenous pathways for the formation and process-
ing of Ang-(1–12), the peptide constitutes a potential substrate for
the conversion to either the active products Ang II or Ang-(1–7).
Ala1-ANGIOTENSIN-(1–7) AND Pro1-Glu2-Ang II
In addition to the precursors to Ang-(1–7), the peptide itself
may serve as a precursor to other active forms. Santos and col-
leagues recently identified an endogenous analog of Ang-(1–7)
in which the aspartic acid residue was decarboxylated to alanine
(Ala) forming Ala1-Ang-(1–7) (Figure 1) (61). The Ala1-Ang-(1–
7) analog (also termed almandine) may also potentially arise from
the proteolytic processing of endogenous Ala1-Ang II (Ang A)
by ACE2 (62). Similar to Ang-(1–7), Ala1-Ang-(1–7) induced the
relaxation of isolated aortic vessels and chronic infusion of the
analog lowered blood pressure. Interestingly, the vascular effects
of Ala1-Ang-(1–7) were not blocked by the typical receptor antago-
nist D-Ala7-Ang-(1–7) (A779) against the Mas receptor, but were
attenuated by D-Pro7-Ang-(1–7) and the AT2 receptor antago-
nist PD123319. This study further showed that Ala7-Ang-(1–7)
stimulated the Mas-related receptor (MrgD) and did not inter-
act with the Mas receptor. Identification of Ala1-Ang-(1–7) in
the human circulation and in an isolated heart perfusion sys-
tem was achieved by a HPLC-Mass spectrometry approach. It is
worth noting that the available direct RIA or ELISA assays will
not distinguish between the Asp1- and Ala1- forms of Ang-(1–7)
since both isoforms share the identical C-terminal sequence that is
typically recognized by the immunoreactive antibodies. Thus, an
initial separation step such as HPLC combined with conventional
immunoreactive assays will be required to routinely detect and
quantify the different forms of Ang-(1–7) in the circulation and
tissues. The potential importance of these findings may reflect the
greater diversity of the Ang-(1–7) axis regarding the identification
of both a novel ligand and receptor that contributes to vascular
tone. Moreover, that the AT2 antagonist PD12319 antagonized the
actions of Ala1-Ang-(1–7) at the MrgD receptor may explain the
apparent interaction of Ang-(1–7) with the AT2 receptor noted in
several studies (63–65).
Although distinct from either Ang-(1–7) or its Ala analog,
Jankowski et al. identified another endogenous ligand to the
AT7/Mas receptor in human serum termed angioprotectin (66).
This peptide resembles the octapeptide Ang II but has substitu-
tions of Pro and Glu at the first two N-terminal residues to form
Pro1-Glu2-Ang II. Despite the fact that the angioprotectin con-
tains both the Tyr4 and Phe8 residues considered to be essential
to the actions of Ang II, the peptide lacked any vasoconstrictor
activity in isolated aortic rings. However, the peptide induced a
dose-dependent vasorelaxation of isolated vessels that was absent
in vessels from the Mas-knockout mice, as well as acutely reduced
blood pressure in the SHR. Moreover, Pro1-Glu2-Ang II stim-
ulated NO formation in Mas-transfected CHO cells but not in
the control cells. Finally, the study presented evidence for local
formation of Pro1-Glu2-Ang II from Ang II in human endothe-
lial cells that was enhanced by addition of exogenous proline
and glutamic acid suggesting a post-transcriptional modification
of Ang II. It is not known to what degree Pro1-Glu2-Ang II is
processed by ACE2 or other carboxypeptidases to the Ang-(1–7)
analog and whether Pro1-Glu2-Ang-(1–7) is functionally active
at the either the Mas or MrgD receptors. It is also unclear the
extent conventional immunoreactive assays for Ang II will detect
endogenous Pro1-Glu2-Ang II in plasma or tissues given their
identical C-terminal sequence. The circulating levels of Pro1-
Glu2-Ang II were 15% of Ang II in humans, but the Ang II
analog increased fivefold in patients with end-stage renal disease
that may perhaps reflect a compensatory response in pathological
conditions (66).
Ang-(1–7) METABOLISM
The endogenous levels of Ang-(1–7) are influenced by access
to processing enzymes such as the carboxypeptidase ACE2 or
the endopeptidases neprilysin, thimet oligopeptidase, and pro-
lyl endopeptidase (oligopeptidase). The levels of Ang-(1–7) are
also dependent on peptidases that metabolize the peptide. Sim-
ilar to bradykinin and substance P, ACE plays a significant
role in the hydrolysis of Ang-(1–7) to the pentapeptide Ang-
(1–5) in the circulation and the proximal tubules of the kid-
ney cortex (Figure 2) (22, 67). ACE inhibition increased the
half-life of Ang-(1–7) sixfold in the circulation and is neces-
sary to demonstrate the accumulation of Ang-(1–7) from both
Ang I- and Ang II-dependent pathways in the renal proximal
tubules (67, 68). Thus, the mechanism for the increased levels of
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Ang-(1–7) following ACE inhibitor treatment reflects both pro-
tection of the peptide from ACE hydrolysis to Ang-(1–5) and
shunting of Ang I to Ang-(1–7) through endopeptidase path-
ways such as neprilysin or thimet oligopeptidase (23). There is
relatively little information on other peptidases that participate
in the metabolism of Ang-(1–7) other than ACE. We recently
detected an endopeptidase activity in the cerebrospinal fluid
(CSF) of sheep that metabolized Ang-(1–7) at the Tyr4-Ile5 bond
to yield Ang-(1–4) and constituted the majority of Ang-(1–7)
degrading activity in CSF (69, 70). Although the identity of
the peptidase is currently unknown, the activity was insensitive
to inhibitors against neprilysin, thimet oligopeptidase, or neu-
rolysin (EC3.4.24.26) (70). The Ang-(1–7) peptidase activity was
abolished by the mercury-compounds p-chloromercuribenzoate
(PCMB) and aminophenyl-mercuriacetate (APMA), as well as the
chelating agents o-phenanthroline and EDTA, but not the cysteine
epoxide inhibitor E-64 suggesting a metallopeptidase-like activity
in CSF (70). The regulation of the CSF peptidase is described in
the proceeding section on fetal programing.
INTRACELLULAR Ang-(1–7)-Mas RECEPTOR SYSTEM
The RAS was traditionally viewed as an endocrine system whereby
circulating renin catalyzes an enzymatic cascade to form active
peptide products; however, it is apparent that multiple tissues
contain the necessary components for the local generation of
angiotensin peptides (71, 72). These tissue systems may release
the precursor angiotensinogen, the intermediate products Ang I
and Ang-(1–12), or the active peptides Ang II and Ang-(1–7) to
bind directly to cell surface receptors in an autocrine or paracrine
manner. Robertson and Khairallah reported over 40 years ago the
localization of Ang II binding sites on the chromatin fraction of
vascular smooth muscle cells and cardiomyocytes suggesting an
intracellular site of action for Ang II (73). Several laboratories sub-
sequently identified Ang II receptors using classical receptor bind-
ing techniques on nuclei isolated from liver (74–76). Eggena and
colleagues demonstrated that Ang II stimulated mRNA transcripts
for angiotensinogen, renin, and PDGF from isolated liver nuclei
suggesting that the nuclear binding sites were functional and capa-
ble of directly mediating gene expression (77, 78). Moreover, AT1
receptors were also evident on nuclei isolated from cortical and
medullary areas of the rat kidney (79–81). Ang II-AT1-receptor
stimulation on isolated renal nuclei increased mRNA expression
of angiotensinogen, the sodium-hydrogen exchanger (NHE3) and
the cytokine monocyte chemoattractant protein (MCP-1) (79).
Ang II also elicited an immediate increase in calcium by iso-
lated cortical nuclei or via microinjection of the peptide in intact
epithelial cells (82). We find that Ang II directly stimulates reactive
oxygen species (ROS) as demonstrated by the enhanced fluores-
cent signature of dichlorofluorescein (DCF); ROS formation was
sensitive to the NAD(P)H oxidase inhibitor diphenyleneiodonium
(DPI) and the AT1 antagonist losartan (83). Blockade of phospho-
inositol 3-kinase (PI3K) and protein kinase C (PKC) abolished
the Ang II-AT1-receptor-dependent stimulation of ROS in renal
nuclei. In lieu of the nuclear localization of the NAD(P)H oxidase
isoform NOX4, activation of AT1 receptors may acutely stimulate
ROS by a PI3K-PKC pathway and subsequent phosphorylation of
NOX4 (Figure 4) (83–87).
The studies demonstrating nuclear AT1 receptors within the
kidney and other tissues clearly support an emerging view for
the localization of various G-protein coupled receptors (GPRCs)
to the nucleus (88–94). In regards to the Ang-(1–7)-Mas receptor
system, O’Dowd and colleagues noted a canonical nuclear localiza-
tion sequence on the Mas protein in their studies on AT1-receptor
trafficking and localization in vascular smooth muscle cells (95).
We undertook a series of studies to establish an intracellular role
for Ang-(1–7) in the cortical tissue and proximal tubules isolated
from the sheep kidney. Immunoblot analysis of nuclei isolated
from sheep proximal tubules demonstrated a single immunoreac-
tive band of 35 kDa utilizing an affinity-purified antibody against
the human Mas protein (96). Receptor binding studies with
the non-selective antagonist 125I-(Sarcosine1, Threonine8)-Ang
II (Sarthran) revealed significant competition by the AT7/Mas
receptor antagonist D-Ala7-Ang-(1–7) in nuclei isolated from the
renal cortex. Functional assessment of the nuclear AT7 receptor
was then assessed with the sensitive NO fluorophore DAF in the
presence or absence of the NO synthase inhibitor L-NAME. Ang-
(1–7) dose-dependently increased the fluorescent signature for
NO which was abolished by prior treatment with L-NAME or the
Ang-(1–7) antagonist, but not antagonists to the AT1 or AT2 recep-
tors. Consistent with the stimulation of NO by Ang-(1–7), protein
expression for endothelial nitric oxide synthase (eNOS) and sol-
uble guanylate cyclase (sGC) was evident in the isolated nuclei of
sheep proximal tubules (96). These data further support previous
studies that localized eNOS and sGC to liver nuclei, as well as the
stimulation of NO and cGMP by activation of the bradykinin B2
receptor (90, 97). The exact function of the Ang-(1–7) axis of the
RAS within the nucleus is not known; however, we hypothesize
this system may antagonize the intracellular actions of the Ang II-
AT1-receptor pathway. To address this possibility, we assessed the
influence of the selective ACE2 inhibitor MLN4760 and the Mas
receptor antagonist on the activation of ROS by Ang II in renal
cortical nuclei. The Ang II-AT1-receptor dependent increase in
ROS was significantly augmented to a similar extent by treatment
of nuclei with either the ACE2 inhibitor or the AT7 receptor antag-
onist (98). That both MLN4760 and D-Ala7-Ang-(1–7) increased
the stimulation of ROS suggests that the conversion to Ang-(1–7)
by ACE2 antagonizes the actions of the Ang II-AT1-receptor axis
on the nucleus. It is possible that that simply blocking the degrada-
tion of Ang II with the ACE2 inhibitor may augment the actions of
Ang II; however, the comparable effects of the AT7 receptor antago-
nist D-Ala7-Ang-(1–7) suggests a distinct role for Ang-(1–7). Since
the Ang-(1–7) antagonist is a peptide and may potentially inter-
act with ACE2, we further demonstrated that D-Ala7-Ang-(1–7)
does not inhibit nuclear ACE2 activity as assessed by the HPLC-
based conversion of Ang II to Ang-(1–7). Moreover, our studies
suggest that the processing of Ang II to Ang-(1–7) by ACE2 on
the nuclear membrane leads to the activation of signaling path-
ways distinct from that of Ang II (98). We do not know, however,
whether the attenuation of ROS production by Ang-(1–7) involves
the stimulation of NO or other signaling pathways. As previously
discussed,Ang-(1–7) may attenuate the actions of Ang II and other
growth hormones by the activation of intracellular phosphatases
such as the dual specificity phosphatases MKP-1 and SHP-1 (50,
51). Several classes of phosphatases including MKP-1 traffic to the
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nucleus; however, it is unknown whether Ang-(1–7) can influence
these enzymes to attenuate the actions of Ang II (99).
Clearly, one issue regarding the intracellular RAS and other
peptidergic systems is the localization of the components within
the cell. The nucleus is composed of two distinct bilayers termed
the outer (OMN) and inner (INM) nuclear membranes. Nuclear
pore proteins traverse both membrane domains and facilitate
transport between the cytosol and the nuclear matrix which con-
tains the chromatin-DNA complex. Portions of the ONM are
continuous with the endoplasmic reticulum (ER) such that peri-
nuclear space is shared with the ER. The nuclear envelope com-
prising both OMN and INM invaginates into the nuclear matrix
creating a nuclear reticulum that is key in the regulated release of
nuclear Ca2+ (100–102). Although various studies have localized
GPRCs primarily to the nuclear envelope and matrix, it is cur-
rently unclear how the peptide ligands target the nuclear GPRCs,
as well as the precise coupling of the receptors to their signaling
pathways within the nucleus. Moreover, elucidation of the path-
ways that deliver peptide ligands to their respective intracellular
receptors, as well as the intracellular regulation under normal and
pathological conditions has not been established. As to the intra-
cellular expression of angiotensins in the kidney, there is evidence
for expression and uptake of angiotensinogen, as well as the uptake
of Ang II and Ang-(1–7) by protein transporters such as megalin
(71, 103–106). In addition, AT1-receptor mediated internalization
of Ang II may contribute to the intracellular content of the pep-
tide (72, 89). In this regard, intracellular peptidases such as ACE2
may potentially process the internalized Ang II to Ang-(1–7) as
alternative pathway to attenuate AT1-receptor activity and stimu-
late the cellular actions of Ang-(1–7). Utilizing the renal epithelial
NRK-52E cell line, we find evidence for the nuclear localization of
angiotensinogen (Figure 3, left panels) consistent with earlier find-
ings by Sherrod and colleagues regarding nuclear angiotensinogen
in brain astrocytes and isolated nuclei of sheep proximal tubules
(96, 107, 108). Interestingly, a second antibody directed to the Ang
I sequence of angiotensinogen failed to detect the protein in the
nucleus of the NRK-52E cells suggesting that enzymatic process-
ing of the precursor may occur in this compartment (107). In
support of an intracellular processing pathway, renin expression
was also evident in the nucleus of the NRK cells (Figure 3, right
panels). Isolated nuclei exhibited both renin and prorenin activity
(following activation by trypsin) that was sensitive to the specific
renin inhibitor aliskiren (Figure 3, bottom left panel), as well as
immunoreactive levels of Ang II and Ang-(1–7) (107). In addi-
tion, peptide metabolism studies in isolated nuclei revealed the
direct conversion of Ang I to Ang-(1–7) that was essentially abol-
ished by a selective inhibitor (CPP) of the metalloendopeptidase
thimet oligopeptidase (Figure 3, bottom right panel). Others have
reported the nuclear expression of thimet oligopeptidase in brain,
as well as the identification of a nuclear localization sequence for
the human peptidase (109, 110). The NRK-52E cells may consti-
tute a relevant cell model to establish the pathways that contribute
to the intracellular generation and actions of Ang II and Ang-(1–7)
within renal epithelial cells. As an alternative concept to intra-
cellular formation, Ibarra and colleagues presented evidence for
another model of nuclear signaling whereby the plasma membrane
invaginates to the perinuclear area that facilitates presentation
FIGURE 3 | Expression of intracellular components of the
renin-angiotensin system in NRK-52E renal epithelial cells.
Immunofluorescent (IMF) staining and protein immunoblot for rat
angiotensinogen (Aogen) and renin. Immunoblots of Aogen and renin in
nuclei (lanes 1–3) and cytosol (lanes 4–6) were from three separate
passages of NRK-52E cells. Major bands for Aogen and renin were
identified at approximately 55 kDa. Renin activity (conversion of Aogen to
Ang I) in isolated nuclear fractions was increased threefold following
activation by trypsin (TRP) and was essentially abolished by the renin
inhibitor aliskiren (ALK). Conversion of 125I-Ang I to 125I-Ang-(1–7) in the
isolated nuclear fraction was predominantly blocked by the thimet
oligopeptidase inhibitor CPP. Renin activity data are mean±SEM; n=4;
*P<0.05. Ang I metabolism representative of data from n=4 separate cell
passages. Adapted from Alzayadneh and Chappell (107).
of intracellular signals (IGF receptor coupled to IP3 formation)
discretely to the nucleus in cardiomyocytes (111). The apparent
advantages of this system may reflect a more selective activation of
the signaling cascade and independence from the intracellular gen-
eration of the peptide ligands (112). The latter study adds another
potential mechanism to the complex pathways of the intracellu-
lar receptor system for angiotensins and other peptides, as well
as emphasize the need for additional studies to elucidate their
organization and function.
In the endeavor to elucidate the intracellular pathways, the
importance of robust biochemical and molecular techniques to
characterize the RAS cannot be overly emphasized. Several reports
have raised concerns regarding the specificity of commercial
AT1 and AT2 antibodies widely utilized for western immunoblot
and immunocytochemical distribution studies (113–115). Impor-
tantly, these studies find that receptor protein bands at the appro-
priate molecular weights were not abolished in AT1- or AT2-
deleted cell and tissue samples. We have utilized antibodies to
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both AT1 and AT2 receptors to establish their molecular weight in
the nuclear fraction as this pertains to the maturation or process-
ing of the receptor protein. However, studies by our laboratory
and others also incorporate peptide binding assays to quantitate
receptor density and affinity, as well as various antagonists to iden-
tify the receptor subtype. The receptor binding assays also parallel
the demonstration of functional signaling pathways (ROS, NO) on
nuclei and the sensitivity to receptor antagonists. Reliance on the
assessment of mRNA for the receptor may not equate to protein
expression and certainly does not reveal the discrete intracellular
distribution of the receptor. Antibodies to angiotensin receptors
or other RAS components are useful and convenient tools to char-
acterize this system; however, parallel approaches to establish the
expression and regulation of the RAS particularly within the cell
are clearly warranted.
FETAL PROGRAMING
Increasing evidence for the influence of early prenatal events in
the fetus to induce a greater susceptibility to cardiovascular and
metabolic pathologies is evident in both experimental models
and in humans (116–119). Although the precise nature of fetal
programing events is not known, alterations in the biochemical
components and functional aspects of the RAS may constitute an
important underlying mechanism (69, 120–128). Our recent stud-
ies utilize a sheep model of fetal programing in which pregnant
ewes are administrated the glucocorticoid betamethasone at day
80 of gestation. This regimen parallels the dose and time that preg-
nant women are typically treated with glucocorticoids to enhance
pulmonary function and reduce mortality of the fetus delivered
preterm. Fetal exposure to glucocorticoids in sheep results in a
significant reduction in the nephron number within the kidney,
an increase in mean blood pressure, attenuation of the barore-
flex response (BRS) in the control of heart rate and increased
indices of metabolic dysfunction in adult animals (129) (Figure 4).
In regards to the function of the RAS following glucocorticoid
exposure, acute treatment with the AT1-receptor antagonist can-
desartan normalized blood pressure in the exposed sheep and
improved the impaired BRS, but had no overall effect on pres-
sure in the control or unexposed adult sheep (129). In contrast,
administration of D-Ala7-Ang-(1–7) increased blood pressure and
attenuated BRS in the control but not the betamethasone-exposed
(BMS) sheep suggesting that the loss of Ang-(1–7) tone may be an
additional consequence of fetal programing events (126). The pro-
tein expression of the AT7/Mas receptor was significantly lower in
the brain medulla in both 6-month- and 1.8-year-old BMS sheep
as compared to age-matched control sheep; however, the AT1-
receptor protein expression was unchanged (122). We also find
reduced CSF levels of Ang-(1–7) in the exposed sheep, as well as
higher activities of the Ang-(1–7) peptidase (Figure 4) (69, 70).
Indeed, the CSF content of Ang-(1–7) inversely correlated to Ang-
(1–7) peptidase activity in the control and BMS sheep (Figure 4,
lower right panel). Thus, the reduced expression of the AT7/Mas
receptor and increased metabolism of Ang-(1–7) in brain may
contribute to the loss of Ang-(1–7) tone in BMS sheep, as well
as the enhanced responsiveness of the Ang II-AT1-receptor path-
way in glucocorticoid-dependent programing without significant
changes in the AT1-receptor levels.
FIGURE 4 | Betamethasone-exposed (BMS) offspring exhibit higher
mean arterial pressure (MAP) and CSF endopeptidase activity than
non-exposed sheep. Blood pressure (MAP) was higher in BMS animals at
6 months of age. CSF peptidase activity was twofold higher in BMS animals
as compared to controls. CSF Ang-(1–7) peptide levels were lower in BMS
animals. Ang-(1–7) peptide levels negatively correlate with peptidase activity
in the CSF (r =−0.81, P =0.01). Data are mean±SEM; 4–5 per group;
*P < 0.05 or ***P <0.001 vs. controls. Adapted from Marshall et al. (70).
In regards to the renal RAS in fetal programing, Ang-(1–7)-
dependent stimulation of sodium excretion was abrogated in the
BMS sheep. Moreover, the anti-natriuretic response to Ang II was
enhanced in the BMS sheep, as well as the reduction in renal plasma
flow (130, 131). Consistent with the altered renal responses to Ang
II and Ang-(1–7), expression of ACE2, the peptidase that con-
tributes to the balance of Ang II to Ang-(1–7), was significantly
reduced in the circulation, the proximal tubules and the urine of
the BMS adult sheep (125). That both tubular and urinary forms
of ACE2 were reduced in the BMS sheep suggests down regula-
tion or reduced synthesis of the peptidase in the proximal tubules
that may lead to the lower release or shedding of the enzyme from
the apical membrane. Both ACE and neprilysin activities were
readily detected in the proximal tubules and urine of adult sheep;
however, their activities were not changed following betametha-
sone exposure. Moreover, circulating ACE activity increased while
ACE2 activity decreased in the serum of BMS adult sheep (125).
A kinetic analysis of ACE2 activity revealed a reduction in the
maximal velocity (Vmax) of the enzyme rather than a change in
substrate affinity (Km) suggesting reduced protein content in the
circulation. These data further suggest that the soluble forms of
the enzyme in serum exhibits similar kinetic characteristics as the
native form, at least regarding the metabolism of Ang II to Ang-
(1–7). The ratio of ACE to ACE2 also closely correlated with the
mean blood pressure values in the control and BMS sheep (125).
In addition to the altered expression of ACE2, the balance of
angiotensin receptor subtypes was changed as well (132). More-
over, the proportion of both AT2 and Mas receptor subtypes were
lower in the renal cortex of the exposed group. However, the
AT1 subtype was the predominant angiotensin receptor in the
renal medulla and the receptor subtypes were unchanged between
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the control and exposed sheep. These data again emphasize the
selective effects of fetal glucocorticoid exposure on expression of
the RAS components within different tissue compartments. The
intracellular studies on the Ang II and Ang-(1–7) signaling path-
ways further support the overall findings that the expression of
angiotensin receptor subtypes were altered following glucocorti-
coid exposure. In isolated nuclei from the real cortex, the gener-
ation of NO by Ang-(1–7) was markedly reduced in the exposed
sheep. In contrast, the Ang II-dependent stimulation of ROS via
the AT1 receptor was augmented in renal nuclei from the BMS
sheep. Furthermore, addition of the AT2 antagonist PD122319
exacerbated the production of ROS by Ang II, and this augmented
response was particularly evident in the glucocorticoid-exposed
group (132). It is not clear whether the AT2 receptor exhibits
functional antagonism of the AT1 receptor to influence ROS for-
mation or that the AT2 subtype sequesters Ang II from the AT1
receptor given the higher ratio of AT2 to AT1 sites in the sheep
cortex.
Finally, fetal programing events may convey greater sensitivity
to an additional stressor or insult, particularly as these animals age
(119). Therefore, recent studies ascertained the renal responses
to Ang-(1–7) in control and glucocorticoid-exposed adult sheep
following removal of one kidney. In contrast to the intact, non-
exposed sheep, Ang-(1–7) infusion reduced sodium excretion in
uni-nephrectomized animals (133). The anti-natriuretic response
to Ang-(1–7) was enhanced by the AT7 receptor antagonist D-
Ala7-Ang-(1–7) and was subsequently blocked by the AT1 antag-
onist candesartan. Moreover, the exposed animals still exhibited
an attenuated natriuretic response to the combination of Ang-
(1–7) and candesartan in comparison to the unexposed con-
trol group. Similar hemodynamic responses were also observed
for Ang-(1–7) in the uni-nephrectomized animals whereby the
peptide alone reduced blood flow and the combination of Ang-
(1–7)/candesartan increased flow; however, the overall vascular
responses were similar between the control and exposed animals
(133). Certainly, differences in species and sex, the primary or
immortalized status of the cells, the dose of both peptide and
antagonists, and the duration of treatment may influence the func-
tional actions of Ang-(1–7) and the receptor(s) mediating these
effects (134). In regards to the studies in the uni-nephrectomized
sheep, the differential response in sodium handling to Ang-(1–7)
likely reflects the compensatory mechanisms of the remaining kid-
ney to accommodate the marked increase in cardiac output and
fluid handling. The fascinating aspect of the renal studies is the
plasticity in the Ang-(1–7) response that apparently encompasses
an AT1 receptor interaction to reduce sodium excretion in the uni-
nephrectomized animal, as well as the Mas receptor interaction
to stimulate sodium excretion in the intact sheep. Moreover, the
natriuretic response of Ang-(1–7) potentially mediated by the Mas
receptor remains intact in the uni-nephrectomized sheep since
it was unmasked by blockade with the AT1-receptor antagonist.
However, the mechanism underlying the functional interaction of
Ang-(1–7) with AT1 receptors in the single kidney is not known,
as well as whether Ang-(1–7) stimulates signaling pathways iden-
tical to that of the Ang II-AT1-receptor axis to reduce sodium
reabsorption and renal blood flow.
SEX DIFFERENCES IN THE Ang-(1–7)-Mas RECEPTOR AXIS
Both experimental and clinical evidence suggest an important
influence of sex on the development of cardiovascular disease
that may reflect the regulation of the RAS by gonadal hormones
including testosterone and estrogen. Women are generally thought
to be protected from cardiovascular pathologies up to the time of
menopause suggesting a beneficial effect of estradiol; however,
several large clinical trials utilizing estrogen or combined estro-
gen/progesterone replacement in older women with underlying
cardiovascular disease revealed adverse effects of either treatment.
Experimental studies have largely focused on the role of estrogen
to influence the ACE-Ang II-AT1-receptor axis of the RAS and
generally reveal an inhibitory effect on the expression of ACE and
the AT1 receptor (135–138). Estrogen depletion by ovariectomy
in young mRen2.Lewis rats markedly exacerbated the hyperten-
sion and essentially abolished sex differences in blood pressure
between the male and female congenics (139). In this model,
estradiol replacement or treatment with the AT1-receptor antag-
onist olmesartan normalized blood pressure suggesting the loss
of estrogen may lead to the dysregulation of the RAS. Indeed,
circulating levels of Ang II and ACE activity were higher in the
estrogen-depleted mRen2.Lewis while plasma levels of Ang-(1–
7) were reduced, and the overall ratio of Ang II to Ang-(1–7)
increased (139, 140). Brosnihan and colleagues originally pro-
posed that the protective effects of estrogen may, in part, reflect
a shift in the balance between circulating Ang II and Ang-(1–7)
that may arise from the inhibitory effects of the steroid on ACE
to promote Ang-(1–7) expression via increased synthesis and/or
reduced metabolism of the peptide (141).
There are relatively few studies that have assessed tissue differ-
ences in Ang II and Ang-(1–7) in males and females. In the kidney
of the mRen2.Lewis hypertensive rats, the tissue content of Ang
II was twofold higher in the males (Figure 5). Conversely, renal
levels of Ang-(1–7) were threefold lower in the males as com-
pared to females. Interestingly, cortical ACE2 activity was 70%
higher in the males perhaps suggesting a compensatory effect to
buffer the higher Ang II content and blood pressure evident in
the male mRen2.Lewis (Figure 5). In contrast, cortical neprilysin
activity and protein expression were significantly higher in the
female congenics as compared to males. The higher content of
the endopeptidase may contribute to the differential expression of
angiotensins in the female kidney to favor the enhanced conver-
sion of Ang I to Ang-(1–7), as well as the metabolism of Ang II to
Ang-(1–4). Cardiac ACE2 activity was also significantly higher in
the male congenics; however, tissue levels of Ang II and Ang-(1–7)
were not different between males and females. The renal content
of Ang-(1–7) was also higher in female SHRs as compared to the
males; however, tissue levels of Ang II were not different (142).
Although this study did not determine peptidase expression in the
SHR kidney as a potential mechanism for the higher Ang-(1–7)
content, tissue levels of Ang-(1–7) were higher in females follow-
ing Ang II treatment perhaps suggesting greater processing of Ang
II to Ang-(1–7). Sandberg and colleagues assessed sex differences
in ACE2 expression in the mouse kidney using the “four core”
approach to distinguish the effect of sex chromosomes and ovar-
ian steroids (143). Consistent with the results in the mRen2.Lewis
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FIGURE 5 | Sex differences in systolic blood pressure and RAS
components in the renal cortex of 15-week-old hemizygous
mRen2.Lewis congenic rats. Systolic blood pressure (mmHg) is higher in
males. Intrarenal concentrations (femtomole peptide per milligram
protein – fmol/mg) of Ang II are higher in males, but Ang-(1–7) content is
lower. ACE2 activity (femtomole product per milligram protein per
minute – fmol/mg/min) is higher in males, but neprilysin (NEP) activity is
lower in males. NEP expression assessed by Western blot was lower in
males (M) as compared to females (F). Data are mean±SEM; n=4–8 per
group; *P< 0.05 or **P<0.01. Adapted from Pendergrass et al. (81).
rats, renal ACE2 activity and expression were higher in the male
mice (143). Ovariectomy increased ACE2 expression in the female
kidney, and estradiol replacement reduced the peptidase in both
males and females; however, there was no influence of gonadal
steroids on either cardiac or pulmonary ACE2 (143). These data
suggest that at least under non-pathological conditions, estro-
gen exhibits an inhibitory influence on kidney ACE2 and raises
the issue of whether this response contributes to the deleteri-
ous effects of estrogen replacement in older women. Cassis and
colleagues reported the sex-dependent expression of circulating
Ang-(1–7) in mice fed a high fat (HF) diet (144). Males exhibited
a marked decline in plasma levels of Ang-(1–7) that was asso-
ciated with higher circulating Ang II; however, plasma levels of
Ang-(1–7) increased in the HF-fed females. Interestingly, ovariec-
tomy of the HF-fed female mice reduced circulating Ang-(1–7) and
ACE2 activity in adipose tissue but did not influence renal ACE2.
The fall in circulating Ang-(1–7) was associated with a marked
increase in nocturnal blood pressure. Moreover, administration of
D-Ala7-Ang-(1–7) increased blood pressure in female mice main-
tained on the HF diet suggesting that the ACE2-Ang-(1–7)-Mas
axis may buffer obesity-induced hypertension to a greater extent
in females.
In regards to the Ang-(1–7) receptor, expression of the Mas
receptor was increased in females but not in males following the
infusion of Ang II which may explain the attenuated blood pres-
sure to Ang II in the females (142). Pretreatment with the AT7
receptor antagonist D-Ala7-Ang-(1–7) enhanced the blood pres-
sure response to Ang II in the female SHR. Similar findings were
recently reported in the aldosterone salt-sensitive model where the
mRNA levels for both ACE2 and the Mas receptor increased 1.5-
and 5-fold, respectively, in the lamina terminalis (LT) of female rats
(145). Chronic ICV treatment with the D-Ala7-Ang-(1–7) antag-
onist markedly augmented the blood pressure response in intact
females treated with aldosterone and sodium chloride. Moreover,
ovariectomy exacerbated the blood pressure response to aldos-
terone/salt; however, the mRNA expression of ACE2 or the Mas
receptor in the LT area was not changed suggesting an inability to
upregulate the central Ang-(1–7) axis contributes to the increase
in blood pressure in this model (145). Denton and colleagues
reported that D-Ala7-Ang-(1–7) alone decreased renal blood flow
in female but not male normotensive Wistar rats, although the
antagonist did not influence the renal response to acute Ang II
infusion in either sex (64). In a separate study, the mRNA levels of
the Mas protein were markedly higher in the kidney of adult female
rats as compared to the males (146). Interestingly, Mas expression
tended to decline in the male kidney while the mRNA levels of
the receptor increased in females over the postnatal period (1–
110 days). Our studies in the sheep model of fetal programing also
provide evidence for sex differences in the responsiveness to Ang-
(1–7). Although the exposure to betamethasone results in a similar
increase in blood pressure and reduction in nephron number in
the male and female sheep, the renal response to Ang-(1–7) or the
antagonist differs with sex. An acute infusion of Ang-(1–7) results
in a robust natriuretic response in control females but not the adult
males (130). Moreover, betamethasone exposure was associated
with reduced natriuresis in the males with or without Ang-(1–
7) treatment, but significantly blunted the natriuretic actions of
Ang-(1–7) in females. At this time, the mechanism underlying
the sex-dependent effects of Ang-(1–7) on sodium excretion in
control and betamethasone-exposed sheep are not known, but we
speculate that it may involve the altered expression or signaling of
the Mas receptor on the tubular elements of the kidney.
SUMMARY
The current review has examined several aspects from the recent
literature on the non-classical or alternative ACE2-Ang-(1–7)-Mas
receptor axis of the RAS. The mounting biochemical and func-
tional evidence clearly supports the tenet that this pathway may
antagonize the ACE-Ang II-AT1-receptor arm of the RAS either
directly through metabolism of Ang II to Ang-(1–7) by ACE2
or via distinct pathways that limit the activation of Ang II-AT1-
receptor signaling. Indeed, the demonstration of an intracellular
ACE2-Ang-(1–7)-Mas axis that attenuates the Ang II-dependent
stimulation of ROS on renal nuclei is in keeping with the con-
cept of a balanced RAS even within the cell and emphasizes the
importance of targeting the intracellular system as a therapeutic
approach to enhance the functional ratio of Ang-(1–7) to Ang
II. The evidence that an altered Ang-(1–7) system within the
brain and the kidney following antenatal glucocorticoid exposure
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implicates an interaction between the Ang II and Ang-(1–7) path-
ways that contribute or promote the cardiovascular dysfunction
associated with fetal programing events. Finally, sex differences
apparent in blood pressure regulation and cardiovascular patholo-
gies may reflect alterations in the ACE2-Ang-(1–7)-Mas receptor
axis of the RAS in addition to those effects typically associated
with the ACE-Ang II-AT1-receptor pathway.
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